A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

A federal appeals court revived a lawsuit that a conservative group brought against Pfizer over one of its fellowship programs.

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

Alzheimer’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...